Related Experiment Videos
[Heart transplantation: secondary prevention]
E Nellessen1, P Lancellotti, J C Demoulin
1Service de Cardiologie, CHU de Liège.
Revue Medicale De Liege
|August 30, 2003
Summary
This review covers immunosuppressive therapy after heart transplantation, detailing drug classes, side effects, rejection types, infections, and cancer risks for improved patient outcomes.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Cardiac transplantation is the primary treatment for end-stage heart failure.
- Immunosuppressive therapy is crucial in the perioperative period to prevent graft rejection.
Purpose of the Study:
- To review immunosuppressive agents used in cardiac transplantation.
- To discuss graft rejection types, associated infections, and cancer risks.
Main Methods:
- Literature review of immunosuppressive agents (calcineurin inhibitors, anti-metabolites, corticosteroids).
- Discussion of general preventive measures and types of rejection (hyperacute, acute vascular, acute cellular, chronic).
- Overview of common infections (bacterial, protozoan, fungal, viral) and cancer risks (skin tumors, non-Hodgkin lymphomas).
Main Results:
- Key immunosuppressive drug classes and their side effects are outlined.
- Different forms of graft rejection and preventive strategies are detailed.
- Infectious complications and oncological risks post-transplant are described.
Conclusions:
- Effective immunosuppression management is vital for successful cardiac allograft survival.
- Monitoring for infections and malignancies is essential for long-term patient health.
- Comprehensive understanding of immunosuppression, rejection, and complications guides clinical practice.